Genovis AB (publ.) (GENO.ST)
SEK 25.0
(2.04%)
SEK 25.0
(2.04%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 54.22 Million SEK | 140.11% |
| 2022 | 22.48 Million SEK | -8.37% |
| 2021 | 24.54 Million SEK | 256.39% |
| 2020 | 6.88 Million SEK | -49.08% |
| 2019 | 13.52 Million SEK | 1507.85% |
| 2018 | -960.64 Thousand SEK | 87.74% |
| 2017 | -7.83 Million SEK | 46.95% |
| 2016 | -14.77 Million SEK | 25.5% |
| 2015 | -19.82 Million SEK | 3.16% |
| 2014 | -20.47 Million SEK | -28.06% |
| 2013 | -15.98 Million SEK | 20.79% |
| 2012 | -20.18 Million SEK | -46.82% |
| 2011 | -13.74 Million SEK | -22.36% |
| 2010 | -11.23 Million SEK | 10.52% |
| 2009 | -12.55 Million SEK | 50.61% |
| 2008 | -25.41 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 2.5 Million SEK | -82.73% |
| 2024 Q1 | 14.57 Million SEK | 565.95% |
| 2023 Q1 | 43.39 Million SEK | 2809.43% |
| 2023 Q2 | 5.98 Million SEK | -86.22% |
| 2023 Q3 | 4.48 Million SEK | -24.96% |
| 2023 FY | 54 Million SEK | 140.11% |
| 2023 Q4 | 2.18 Million SEK | -51.25% |
| 2022 Q2 | 221 Thousand SEK | -97.81% |
| 2022 FY | 22.48 Million SEK | -8.37% |
| 2022 Q3 | 4.99 Million SEK | 2159.28% |
| 2022 Q4 | -1.6 Million SEK | -132.08% |
| 2022 Q1 | 10.1 Million SEK | -53.85% |
| 2021 Q3 | 747 Thousand SEK | -44.67% |
| 2021 Q4 | 21.89 Million SEK | 2830.97% |
| 2021 FY | 24.54 Million SEK | 256.39% |
| 2021 Q1 | 551 Thousand SEK | -88.04% |
| 2021 Q2 | 1.35 Million SEK | 145.01% |
| 2020 Q3 | 1.71 Million SEK | 232.84% |
| 2020 Q4 | 4.6 Million SEK | 168.53% |
| 2020 Q1 | -1.88 Million SEK | -262.15% |
| 2020 FY | 6.88 Million SEK | -49.08% |
| 2020 Q2 | -1.29 Million SEK | 31.66% |
| 2019 FY | 13.52 Million SEK | 1507.85% |
| 2019 Q4 | -521.6 Thousand SEK | -107.43% |
| 2019 Q1 | 1.94 Million SEK | 1.5% |
| 2019 Q2 | 1.62 Million SEK | -16.17% |
| 2019 Q3 | 7.01 Million SEK | 331.14% |
| 2018 Q2 | -1.92 Million SEK | -40.72% |
| 2018 FY | -960.64 Thousand SEK | 87.74% |
| 2018 Q4 | 1.91 Million SEK | 357.74% |
| 2018 Q3 | 418 Thousand SEK | 121.71% |
| 2018 Q1 | -1.36 Million SEK | -19.43% |
| 2017 FY | -7.83 Million SEK | 46.95% |
| 2017 Q4 | -1.14 Million SEK | 30.75% |
| 2017 Q2 | -1.97 Million SEK | 30.91% |
| 2017 Q1 | -2.86 Million SEK | -24.58% |
| 2017 Q3 | -1.65 Million SEK | 16.38% |
| 2016 FY | -14.77 Million SEK | 25.5% |
| 2016 Q4 | -2.29 Million SEK | -114.78% |
| 2016 Q2 | -7.95 Million SEK | -130.59% |
| 2016 Q1 | -3.44 Million SEK | -8.72% |
| 2016 Q3 | -1.07 Million SEK | 86.55% |
| 2015 Q3 | -6.39 Million SEK | -21.54% |
| 2015 Q4 | -3.17 Million SEK | 50.37% |
| 2015 FY | -19.82 Million SEK | 3.16% |
| 2015 Q1 | -5 Million SEK | 18.91% |
| 2015 Q2 | -5.25 Million SEK | -5.18% |
| 2014 Q3 | -5.58 Million SEK | -15.44% |
| 2014 FY | -20.47 Million SEK | -28.06% |
| 2014 Q1 | -3.87 Million SEK | 27.99% |
| 2014 Q2 | -4.83 Million SEK | -24.78% |
| 2014 Q4 | -6.16 Million SEK | -10.39% |
| 2013 Q1 | -3.95 Million SEK | 53.4% |
| 2013 FY | -15.98 Million SEK | 20.79% |
| 2013 Q4 | -5.38 Million SEK | -96.56% |
| 2013 Q3 | -2.74 Million SEK | 29.78% |
| 2013 Q2 | -3.9 Million SEK | 1.39% |
| 2012 FY | -20.18 Million SEK | -46.82% |
| 2012 Q2 | -4.42 Million SEK | -10.56% |
| 2012 Q3 | -3.25 Million SEK | 26.42% |
| 2012 Q4 | -8.49 Million SEK | -160.64% |
| 2012 Q1 | -4 Million SEK | -1.25% |
| 2011 Q1 | -3.46 Million SEK | -5.08% |
| 2011 Q2 | -3.31 Million SEK | 4.36% |
| 2011 Q3 | -3.01 Million SEK | 9.03% |
| 2011 Q4 | -3.95 Million SEK | -31.24% |
| 2011 FY | -13.74 Million SEK | -22.36% |
| 2010 Q2 | -2.73 Million SEK | -17.25% |
| 2010 FY | -11.23 Million SEK | 10.52% |
| 2010 Q1 | -2.33 Million SEK | 29.8% |
| 2010 Q4 | -3.29 Million SEK | -15.26% |
| 2010 Q3 | -2.86 Million SEK | -4.42% |
| 2009 Q3 | -3.01 Million SEK | -5.91% |
| 2009 Q1 | -3.37 Million SEK | 0.0% |
| 2009 FY | -12.55 Million SEK | 50.61% |
| 2009 Q4 | -3.32 Million SEK | -10.55% |
| 2009 Q2 | -2.84 Million SEK | 15.74% |
| 2008 FY | -25.41 Million SEK | 0.0% |
| 2008 Q1 | -4.86 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 121.778% |
| Ziccum AB (publ) | -21.56 Million SEK | 351.503% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | 430.614% |
| BioArctic AB (publ) | 252.64 Million SEK | 78.537% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | 6517.041% |
| Mendus AB (publ) | -100.65 Million SEK | 153.874% |
| Intervacc AB (publ) | -93.57 Million SEK | 157.945% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | 449.562% |
| Active Biotech AB (publ) | -46.48 Million SEK | 216.651% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | -201.094% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 197.847% |
| Aptahem AB (publ) | -10.1 Million SEK | 636.618% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 116.866% |
| Kancera AB (publ) | -65.04 Million SEK | 183.368% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 140.28% |
| Fluicell AB (publ) | -26.87 Million SEK | 301.734% |
| Saniona AB (publ) | -81.06 Million SEK | 166.89% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | 538.315% |
| Biovica International AB (publ) | -126.07 Million SEK | 143.01% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 227.571% |
| AcouSort AB (publ) | -17.48 Million SEK | 410.082% |
| Xintela AB (publ) | -57.23 Million SEK | 194.734% |
| Abliva AB (publ) | -96.54 Million SEK | 156.163% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 116.695% |
| Karolinska Development AB (publ) | -3.5 Million SEK | 1647.047% |
| OncoZenge AB (publ) | -15.9 Million SEK | 440.989% |
| Amniotics AB (publ) | -29.07 Million SEK | 286.51% |
| 2cureX AB (publ) | -36.36 Million SEK | 249.119% |
| CombiGene AB (publ) | -36.3 Million SEK | 249.356% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | 470.383% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 114.106% |
| Camurus AB (publ) | 532.35 Million SEK | 89.814% |
| Corline Biomedical AB | -1.78 Million SEK | 3132.662% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 129.997% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 230.087% |
| I-Tech AB | 24.43 Million SEK | -121.911% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 106.877% |
| Cyxone AB (publ) | -21.66 Million SEK | 350.33% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 151.172% |
| Biosergen AB | -27.26 Million SEK | 298.878% |
| Cantargia AB (publ) | -290.01 Million SEK | 118.697% |
| NextCell Pharma AB | -43.17 Million SEK | 225.6% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 129.997% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | 417.168% |
| Nanologica AB (publ) | -69.96 Million SEK | 177.504% |
| SynAct Pharma AB | -224.49 Million SEK | 124.154% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 222.745% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 326.365% |
| LIDDS AB (publ) | -40.67 Million SEK | 233.314% |
| Lipum AB (publ) | -37.25 Million SEK | 245.552% |
| BioInvent International AB (publ) | -369.94 Million SEK | 114.657% |
| Alzinova AB (publ) | -16.52 Million SEK | 428.193% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 121.395% |
| Pila Pharma AB (publ) | -6.39 Million SEK | 948.145% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 147.121% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | 369.249% |
| Simris Alg AB (publ) | -36.63 Million SEK | 248.011% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 136.996% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 117.468% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 148.888% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | 568.822% |